The combination of an innovative dry powder for inhalation and a standard cisplatin-based chemotherapy in view of therapeutic intensification against lung tumours
Chraibi, S.; Rosiere, R.; Larbanoix, Lionelet al.
2021 • In European Journal of Pharmaceutics and Biopharmaceutics
CMMI - Centre de Recherche en Microscopie et Imagerie Médicale
Disciplines :
Chemistry
Author, co-author :
Chraibi, S.
Rosiere, R.
Larbanoix, Lionel ; Université de Mons > Unités externes > Center for Microscopy and Molecular Imaging
Gerard, P.
hennia, I.
Laurent, Sophie ; Université de Mons > Faculté de Médecine et de Pharmacie > Service de Chimie générale, organique et biomédicale
Vermeech, Marjorie
Amighi, K.
Wauthoz, N.
Language :
English
Title :
The combination of an innovative dry powder for inhalation and a standard cisplatin-based chemotherapy in view of therapeutic intensification against lung tumours
Publication date :
02 January 2021
Journal title :
European Journal of Pharmaceutics and Biopharmaceutics
ISSN :
0939-6411
Publisher :
Elsevier, Amsterdam, Netherlands
Peer reviewed :
Peer Reviewed verified by ORBi
Research unit :
M108 - Chimie générale, organique et biomédicale
Research institute :
R550 - Institut des Sciences et Technologies de la Santé R100 - Institut des Biosciences
F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA. Cancer J. Clin. 68 (2018) 394–424. https://doi.org/10.3322/caac.21492.
National Comprehensive Cancer Network Guidelines - Non-Small Cell Lung Cancer - Version 3.2020, 2020.
Duma, N., Santana-Davila, R., Molina, J.R., Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin. Proc. 94 (2019), 1623–1640, 10.1016/j.mayocp.2019.01.013.
Passiglia, F., Pilotto, S., Facchinetti, F., Bertolaccini, L., Del Re, M., Ferrara, R., Franchina, T., Malapelle, U., Menis, J., Passaro, A., Ramella, S., Rossi, G., Trisolini, R., Novello, S., Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. Crit. Rev. Oncol. Hematol., 146, 2020, 102862, 10.1016/j.critrevonc.2019.102858.
M. Majem, O. Juan, A. Insa, N. Reguart, J.M. Trigo, E. Carcereny, R. García-Campelo, Y. García, M. Guirado, M. Provencio, SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018), Clin. Transl. Oncol. 21 (2019) 3–17. https://doi.org/10.1007/s12094-018-1978-1.
Hanna, N.H., Schneider, B.J., Temin, S., Jr, S.B., Brahmer, J., Therapy for Stage IV Non – Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline. Update, 2020, 10.1200/JCO.19.03022.
Karasawa, T., Steyger, P.S., An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol. Lett. 237 (2015), 219–227, 10.1016/j.toxlet.2015.06.012.
Kim, E.S., Lee, J.J., He, G., Chow, C.-W., Fujimoto, J., Kalhor, N., Swisher, S.G., Wistuba, I.I., Stewart, D.J., Siddik, Z.H., Tissue platinum concentration and tumor response in non-small-cell lung cancer. J. Clin. Oncol. 30 (2012), 3345–3352, 10.1200/JCO.2011.40.8120.
Kim, J.J., Tannock, I.F., Repopulation of cancer cells during therapy: An important cause of treatment failure. Nat. Rev. Cancer 5 (2005), 516–525, 10.1038/nrc1650.
V.F. Vasconcellos, G.N. Marta, E.M. da Silva, A.F. Gois, T.B. de Castria, R. Riera, Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer, Cochrane Database Syst. Rev. 1 (2020) CD009256. https://doi.org/10.1002/14651858.CD009256.pub3.
Ghi, M.G., Paccagnella, A., Therapeutic Intensification and Induction Chemotherapy for High-Risk Locally Advanced Squamous Cell Carcinoma. Curr. Treat. Options Oncol. 20 (2019), 1–15, 10.1007/s11864-019-0599-4.
Kalman, N.S., Weiss, E., Walker, P.R., Rosenman, J.G., Local Radiotherapy Intensification for Locally Advanced Non–small-cell Lung Cancer – A Call to Arms. Clin. Lung Cancer. 19 (2018), 17–26, 10.1016/j.cllc.2017.05.024.
Wauthoz, N., Rosière, R., Amighi, K., Expert Opinion on Drug Delivery Inhaled cytotoxic chemotherapy: clinical challenges, recent developments, and future prospects future prospects. Expert Opin. Drug Deliv. 00 (2021), 1–22, 10.1080/17425247.2021.1829590.
Rosière, R., Berghmans, T., de Vuyst, P., Amighi, K., Wauthoz, N., The position of inhaled chemotherapy in the care of patients with lung tumors: Clinical feasibility and indications according to recent pharmaceutical progresses. Cancers (Basel)., 11, 2019, 10.3390/cancers11030329.
Chou, A.J., Gupta, R., Bell, M.D., Riewe, K.O., Meyers, P.A., Gorlick, R., Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. Pediatr. Blood Cancer 60 (2013), 580–586, 10.1002/pbc.24438.
Wittgen, B.P.H., Kunst, P.W.A., van der Born, K., van Wijk, A.W., Perkins, W., Pilkiewicz, F.G., Perez-Soler, R., Nicholson, S., Peters, G.J., Postmus, P.E., Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin. Cancer Res. 13 (2007), 2414–2421, 10.1158/1078-0432.CCR-06-1480.
Levet, V., Merlos, R., Rosière, R., Amighi, K., Wauthoz, N., Platinum pharmacokinetics in mice following inhalation of cisplatin dry powders with different release and lung retention properties. Int. J. Pharm. 517 (2017), 359–372, 10.1016/j.ijpharm.2016.12.037.
Levet, V., Rosière, R., Merlos, R., Fusaro, L., Berger, G., Amighi, K., Wauthoz, N., Development of controlled-release cisplatin dry powders for inhalation against lung cancers. Int. J. Pharm. 515 (2016), 209–220, 10.1016/j.ijpharm.2016.10.019.
V. Levet, R. Rosiere, J. Hecq, I. Langer, K. Amighi, N. Wauthoz, Tolerance of Cisplatin Dry Powders for Inhalation and Efficacy on an Orthotopic Grafted Lung Tumor Preclinical Model, in: R. Dalby, P. Byron, J. Peart, J. Suman, P. Young, D. Traini (Eds.), RDD Eur. 2017, DHI Publishing, River Grove, IL, 2017: pp. 335–340.
Son, Y.-J., McConville, J.T., Development of a standardized dissolution test method for inhaled pharmaceutical formulations. Int. J. Pharm. 382 (2009), 15–22, 10.1016/J.IJPHARM.2009.07.034.
Hoppentocht, M., Hoste, C., Hagedoorn, P., Frijlink, H.W., De Boer, A.H., In vitro evaluation of the DP-4M PennCenturyTM insufflator. Eur. J. Pharm. Biopharm. 88 (2014), 153–159, 10.1016/j.ejpb.2014.06.014.
Rosière, R., Van Woensel, M., Mathieu, V., Langer, I., Mathivet, T., Vermeersch, M., Amighi, K., Wauthoz, N., Development and evaluation of well-tolerated and tumor-penetrating polymeric micelle-based dry powders for inhaled anti-cancer chemotherapy. Int. J. Pharm. 501 (2016), 148–159, 10.1016/j.ijpharm.2016.01.073.
Bar, I., Merhi, A., Larbanoix, L., Constant, M., Haussy, S., Laurent, S., Canon, J.L., Delrée, P., Silencing of casein kinase 1 delta reduces migration and metastasis of triple negative breast cancer cells. Oncotarget. 9 (2018), 30821–30836 https://doi.org/10.18632/oncotarget.25738.
Wauthoz, N., Deleuze, P., Hecq, J., Roland, I., Saussez, S., Adanja, I., Debeir, O., Decaestecker, C., Mathieu, V., Kiss, R., Amighi, K., In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy. Eur. J. Pharm. Sci. 39 (2010), 402–411, 10.1016/j.ejps.2010.01.010.
D.N. Price, N.K. Kunda, P. Muttil, Challenges Associated with the Pulmonary Delivery of Therapeutic Dry Powders for Preclinical Testing, KONA Powder Part. J. advpub (2019). https://doi.org/10.14356/kona.2019008.
Vouillamoz-Lorenz, S., Bauer, J., Lejeune, F., Decosterd, L.A., Validation of an AAS method for the determination of platinum in biological fluids from patients receiving the oral platinum derivative JM216. J. Pharm. Biomed. Anal. 25 (2001), 465–475, 10.1016/S0731-7085(00)00508-2.
Inactive Ingredient Search for Approved Drug Products, (n.d.).
T. Riley, D. Christopher, J. Arp, A. Casazza, A. Colombani, A. Cooper, M. Dey, J. Maas, Challenges with developing in vitro dissolution tests for orally inhaled products(OIPs), (2012). https://doi.org/10.1208/s12249-012-9822-3.
Velaga, S.P., Djuris, J., Cvijic, S., Rozou, S., Russo, P., Colombo, G., Rossi, A., Dry powder inhalers: An overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products. Eur. J. Pharm. Sci. 113 (2018), 18–28, 10.1016/j.ejps.2017.09.002.
Pilcer, G., Amighi, K., Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 392 (2010), 1–19, 10.1016/j.ijpharm.2010.03.017.
European pharmacopea, 9, 2020.
G.S. Zijlstra, Dry powder inhalation of biopharmaceuticals: from formulation to proof-of-concept, 2009.
Urien, S., Brain, E., Bugat, R., Pivot, X., Lochon, I., Vo Van, M.L., Vauzelle, F., Lokiec, F., Pharmacokinetics of platinum after oral or intravenous cisplatin: A phase 1 study in 32 adult patients. Cancer Chemother. Pharmacol. 55 (2005), 55–60, 10.1007/s00280-004-0852-8.
Abdou, E.M., Kandil, S.M., Morsi, A., Sleem, M.W., In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug. Drug Deliv. 26 (2019), 689–699, 10.1080/10717544.2019.1618419.
Depreter, F., Burniat, A., Blocklet, D., Lacroix, S., Cnop, M., Fery, F., Van Aelst, N., Pilcer, G., Deleers, M., Goldman, S., Amighi, K., Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients. Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Für Pharm. Verfahrenstechnik e.V. 80 (2012), 4–13, 10.1016/j.ejpb.2011.09.015.
Newhouse, M.T., Hirst, P.H., Duddu, S.P., Walter, Y.H., Tarara, T.E., Clark, A.R., Weers, J.G., Inhalation of a dry powder tobramycin pulmosphere formulation in healthy volunteers. Chest 124 (2003), 360–366, 10.1378/chest.124.1.360.
Chraibi, S., Rosière, R., De Prez, E., Antoine, M.H., Remmelink, M., Langer, I., Nortier, J., Amighi, K., Wauthoz, N., Pulmonary and renal tolerance of cisplatin-based regimens combining intravenous and endotracheal routes for lung cancer treatment in mice - In press. 2021, Int. J, Pharm.
Brouwers, E.E.M., Huitema, A.D.R., Beijnen, J.H., Schellens, J.H.M., Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin. Pharmacol. 8 (2008), 1–10, 10.1186/1472-6904-8-7.
Rosière, R., Bischof, R., Chraibi, S., Gérard, P., Hennia, I., Meeusen, E., Amighi, K., Wauthoz, N., Pharmacokinetic and Preliminary Toxicity Investigation of an Innovative Controlled- Release Cisplatin Dry Powder Inhalation Formulation in Sheep, in. RDD Eur., 2020, 2020, 521–526.
Yao, X., Panichpisal, K., Kurtzman, N., Nugent, K., Cisplatin Nephrotoxicity: A Review. Am. J. Med. Sci. 334 (2007), 115–124, 10.1097/MAJ.0B013E31812DFE1E.
Manohar, S., Leung, N., Cisplatin nephrotoxicity: a review of the literature. J. Nephrol. 31 (2018), 15–25, 10.1007/s40620-017-0392-z.
Zarogoulidis, P., Eleftheriadou, E., Sapardanis, I., Zarogoulidou, V., Lithoxopoulou, H., Kontakiotis, T., Karamanos, N., Zachariadis, G., Mabroudi, M., Zisimopoulos, A., Zarogoulidis, K., Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Invest. New Drugs 30 (2012), 1628–1640, 10.1007/s10637-011-9714-5.
Zarogoulidis, P., Darwiche, K., Krauss, L., Huang, H., Zachariadis, G.A., Katsavou, A., Hohenforst-Schmidt, W., Papaiwannou, A., Vogl, T.J., Freitag, L., Stamatis, G., Zarogoulidis, K., Inhaled cisplatin deposition and distribution in lymph nodes in stage II lung cancer patients. Futur. Oncol. 9 (2013), 1307–1313, 10.2217/fon.13.111.
